The CeRNA Network Regulates Epithelial-mesenchymal Transition in Colorectal Cancer

Overview

Journal Heliyon

Specialty Social Sciences

Date 2023 Mar 23

PMID 36950593

Authors

Ruina Li

Hui Xu

Xiaoling Gao

Affiliations

Soon will be listed here.

Abstract

Epithelial-mesenchymal transition (EMT) is a biological process that transforms epithelial cells into a mesenchymal phenotype, conferring cell migration and invasion capabilities. EMT is involved in the progression and metastasis of colorectal cancer (CRC). Recently, emerging evidence has shown dysregulation of non-coding RNA (ncRNA) was linked to EMT. ncRNAs, including long non-coding RNA (lncRNA), regulate the transcription of downstream target genes (mRNA) through interaction with microRNAs (miRNAs); these are termed competitive endogenous RNA (ceRNA) networks. CeRNA dysregulation-induced EMT, which is linked to the progression and prognosis of CRC, has attracted wide attention. However, understanding the role of the regulation of the ceRNA network in the EMT of CRC remains limited. We discuss the molecular functions of lncRNA, the ceRNA networks related to miRNAs and mRNAs in EMT, as well as EMT transcription factors, such as the zinc finger E-box binding homeobox 1/2 (ZEB1/2), SNAIL, SLUG, and TWIST1/2. In addition, miRNAs and lncRNAs that directly target genes, thereby initiating different signaling pathways to promote EMT in CRC, were summarized. Clarifying the role of these molecules in EMT is critical for understanding molecular mechanisms and exploring the potential therapeutic targets of CRC.

Citing Articles

CircRNAs in Colorectal Cancer: Unveiling Their Roles and Exploring Therapeutic Potential.

Ding Y, Song X, Chen J Biochem Genet. 2025; .

PMID: 40029586 DOI: 10.1007/s10528-025-11068-5.

Deciphering the oncogenic network: how C1QTNF1-AS1 modulates osteosarcoma through miR-34a-5p and glycolytic pathways.

Zhang Y, Lun H, Zhu N, Yang N, Ding K, Chen B Front Oncol. 2025; 14():1485605.

PMID: 39850812 PMC: 11754200. DOI: 10.3389/fonc.2024.1485605.

LINC02257 regulates malignant phenotypes of colorectal cancer via interacting with miR-1273g-3p and YB1.

Park M, Jeong S, Shin C, Cha S, Yu A, Kim E Cell Death Dis. 2024; 15(12):895.

PMID: 39695079 PMC: 11655847. DOI: 10.1038/s41419-024-07259-4.

Comprehensive Multi-Omics Analysis Reveals NPC2 and ITGAV Genes as Potential Prognostic Biomarkers in Gastrointestinal Cancers.

Piroozkhah M, Zabihi M, Jalali P, Salehi Z Cancer Rep (Hoboken). 2024; 7(12):e70087.

PMID: 39690926 PMC: 11652787. DOI: 10.1002/cnr2.70087.

Circ_0001944 Targets the miR-1292-5p/FBLN2 Axis to Facilitate Sorafenib Resistance in Hepatocellular Carcinoma by Impeding Ferroptosis.

Jing F, Shi Y, Jiang D, Li X, Sun J, Guo Q Immunotargets Ther. 2024; 13:643-659.

PMID: 39624827 PMC: 11611519. DOI: 10.2147/ITT.S463556.

References

Usman S, Waseem N, Nguyen T, Mohsin S, Jamal A, Teh M . Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis. Cancers (Basel). 2021; 13(19). PMC: 8507690. DOI: 10.3390/cancers13194985. View

Li Z, Shen J, Chan M, Wu W . TUG1: a pivotal oncogenic long non-coding RNA of human cancers. Cell Prolif. 2016; 49(4):471-5. PMC: 6496395. DOI: 10.1111/cpr.12269. View

Liu A, Liu L, Lu H . LncRNA XIST facilitates proliferation and epithelial-mesenchymal transition of colorectal cancer cells through targeting miR-486-5p and promoting neuropilin-2. J Cell Physiol. 2019; 234(8):13747-13761. DOI: 10.1002/jcp.28054. View

Liu X, Cui L, Hua D . Long Noncoding RNA XIST Regulates miR-137-EZH2 Axis to Promote Tumor Metastasis in Colorectal Cancer. Oncol Res. 2018; 27(1):99-106. PMC: 7848292. DOI: 10.3727/096504018X15195193936573. View

Chen X, Xu X, Pan B, Zeng K, Xu M, Liu X . miR-150-5p suppresses tumor progression by targeting VEGFA in colorectal cancer. Aging (Albany NY). 2018; 10(11):3421-3437. PMC: 6286841. DOI: 10.18632/aging.101656. View

Seo J, Ha J, Kang E, Cho S . The role of epithelial-mesenchymal transition-regulating transcription factors in anti-cancer drug resistance. Arch Pharm Res. 2021; 44(3):281-292. PMC: 8009775. DOI: 10.1007/s12272-021-01321-x. View

Cheriyamundath S, Ben-Zeev A . Wnt/β-Catenin Target Genes in Colon Cancer Metastasis: The Special Case of L1CAM. Cancers (Basel). 2020; 12(11). PMC: 7699470. DOI: 10.3390/cancers12113444. View

Liang W, Fu W, Wong C, Wang Y, Wang W, Hu G . The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget. 2015; 6(26):22513-25. PMC: 4673179. DOI: 10.18632/oncotarget.4154. View

Alizadeh A, Jebelli A, Baradaran B, Amini M, Oroojalian F, Hashemzaei M . Crosstalk between long non-coding RNA DLX6-AS1, microRNAs and signaling pathways: A pivotal molecular mechanism in human cancers. Gene. 2020; 769:145224. DOI: 10.1016/j.gene.2020.145224. View

10.

Sun Y, Gao X, Li P, Song L, Shi L . LncRNA ZFAS1, as a poor prognostic indicator, promotes cell proliferation and epithelial-mesenchymal transition in endometrial carcinoma. Per Med. 2020; 18(1):43-53. DOI: 10.2217/pme-2020-0014. View

11.

Tewari D, Bawari S, Sharma S, DeLiberto L, Bishayee A . Targeting the crosstalk between canonical Wnt/β-catenin and inflammatory signaling cascades: A novel strategy for cancer prevention and therapy. Pharmacol Ther. 2021; 227:107876. DOI: 10.1016/j.pharmthera.2021.107876. View

12.

Yang W, Ning N, Jin X . The lncRNA H19 Promotes Cell Proliferation by Competitively Binding to miR-200a and Derepressing -Catenin Expression in Colorectal Cancer. Biomed Res Int. 2017; 2017:2767484. PMC: 5259610. DOI: 10.1155/2017/2767484. View

13.

Fang C, Zan J, Yue B, Liu C, He C, Yan D . Long non-coding ribonucleic acid zinc finger antisense 1 promotes the progression of colonic cancer by modulating ZEB1 expression. J Gastroenterol Hepatol. 2016; 32(6):1204-1211. DOI: 10.1111/jgh.13646. View

14.

Hussen B, Shoorei H, Mohaqiq M, Dinger M, Hidayat H, Taheri M . The Impact of Non-coding RNAs in the Epithelial to Mesenchymal Transition. Front Mol Biosci. 2021; 8:665199. PMC: 8033041. DOI: 10.3389/fmolb.2021.665199. View

15.

Dariya B, Aliya S, Merchant N, Alam A, Nagaraju G . Colorectal Cancer Biology, Diagnosis, and Therapeutic Approaches. Crit Rev Oncog. 2021; 25(2):71-94. DOI: 10.1615/CritRevOncog.2020035067. View

16.

Ogunwobi O, Mahmood F, Akingboye A . Biomarkers in Colorectal Cancer: Current Research and Future Prospects. Int J Mol Sci. 2020; 21(15). PMC: 7432436. DOI: 10.3390/ijms21155311. View

17.

Liu C, Hu C, Li J, Jiang L, Zhao C . Identification of Epithelial-Mesenchymal Transition-Related lncRNAs that Associated With the Prognosis and Immune Microenvironment in Colorectal Cancer. Front Mol Biosci. 2021; 8:633951. PMC: 8059639. DOI: 10.3389/fmolb.2021.633951. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Yang Y, Feng M, Bai L, Liao W, Zhou K, Zhang M . Comprehensive analysis of EMT-related genes and lncRNAs in the prognosis, immunity, and drug treatment of colorectal cancer. J Transl Med. 2021; 19(1):391. PMC: 8444417. DOI: 10.1186/s12967-021-03065-0. View

20.

Winkle M, El-Daly S, Fabbri M, Calin G . Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. 2021; 20(8):629-651. PMC: 8212082. DOI: 10.1038/s41573-021-00219-z. View